查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933304

全球慢性腰痛治療市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Chronic Lower Back Pain Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

慢性腰痛 (CLBP) 治療市場成長因子

由於慢性疼痛疾病盛行率的上升以及對長期疼痛管理解決方案的日益重視，全球慢性腰痛 (CLBP) 治療市場正經歷強勁增長。根據本報告，預計到 2025 年，市場規模將達到 28.4 億美元，到 2026 年將成長至 31 億美元，到 2034 年將達到 69.5 億美元，預測期內複合年增長率 (CAGR) 為 10.63%。北美地區在 2025 年將以 47.90% 的市場佔有率領先，這得益於該地區較高的疾病負擔、完善的醫療保健基礎設施以及積極的藥物研發。

市場概覽

慢性腰痛 (LCP) 是全球最常見的肌肉骨骼疾病之一，也是導致殘疾的主要原因之一。這種疾病通常與骨關節炎、椎間盤退化性病變、肥胖、焦慮和年齡相關疾病有關。慢性下背痛的治療包括藥物治療，如非類固醇抗發炎藥 (NSAIDs)、鴉片類藥物、抗憂鬱藥和鎮痛藥，以及非藥物治療，如復健和物理治療。由於診斷延遲和認知不足造成的經濟負擔日益加重，世界各國政府正在推出旨在早期管理和改善治療效果的指南和政策。

市場驅動因素

慢性腰痛盛行率的不斷上升是市場成長的主要驅動因素。久坐的生活方式、肥胖、心理壓力和人口老化正在顯著增加需要長期疼痛管理的患者數量。 政府推出的 "澳洲醫療保健差異圖譜" （Australian Healthcare Variance Atlas）等舉措，例如2022年推出的，正在推動公眾意識的提高和早期幹預的開展，從而提升治療需求。此外，製藥公司也正在加速研發，以推出能夠有效且持久緩解疼痛的創新藥物。

市場趨勢

影響市場的關鍵趨勢是利用先進的藥物傳遞技術來減少對傳統鴉片類藥物的依賴。由於長期使用鴉片類藥物與成癮和副作用有關，研究人員正致力於開發更安全的替代方案，例如局部用藥和透皮給藥系統。目前，多種藥物，例如Sorrento Therapeutics公司的SP-103和帝國製藥公司的氟比洛芬貼劑，正處於臨床開發階段，這反映了該市場強勁的創新勢頭。

新冠疫情的影響

由於非緊急醫療諮詢減少以及疼痛管理療法的可近性受限，新冠疫情在2020年暫時減緩了市場成長。在此期間，藥物和非藥物治療（尤其是非類固醇抗發炎藥）的使用量有所下降。然而，疫情後的復甦勢頭強勁，非處方止痛藥的需求增加，研發活動也重新受到重視。自2021年起，新鎮痛產品的上市和銷售額的成長支撐了收入的正面成長。

市場區隔分析

依藥物類別劃分，非類固醇抗發炎藥（NSAIDs）佔市場主導地位，預計到2026年將佔25.77%的市場佔有率。這主要歸功於其價格實惠、療效顯著以及無需處方即可購買等優勢。 鴉片類藥物主要用於緩解劇烈疼痛，佔第二大市場。同時，抗憂鬱藥和止痛藥因其在慢性疼痛管理方面的有效性，也為市場收入做出了顯著貢獻。

依給藥途徑劃分，口服給藥途徑在2026年將佔市場主導地位，市佔率達44.38%。這主要得益於患者依從性高、使用方便性以及成本效益高等因素。 由於局部用藥製劑（如凝膠和軟膏）能夠提供局部且暫時的止痛效果，因此其市佔率也穩定成長。

依分銷管道劃分，受便利性提升、線上平台擴張以及非處方止痛藥供應增加的推動，零售藥局和線上藥局將在2026年佔91.83%的市場佔有率。

區域洞察

北美地區將繼續保持領先地位，預計到2025年市場規模將達到13.6億美元，這主要得益於先進的藥物研發活動和慢性疼痛的高發生率。亞太地區預計將實現最快的成長速度，這主要得益於價格實惠的仿製藥和人口老化。歐洲預計將成為成長第二快的地區，這主要歸因於久坐的生活方式和肌肉骨骼疾病的增加。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 主要國家慢性腰痛盛行率（2026 年）
  • 主要公司產品線分析
  • 主要公司關鍵產業趨勢
  • 新冠疫情對市場的影響

第五章 全球慢性腰痛治療市場分析：洞察與預測（2021-2034 年）

  • 市場分析、洞察與預測：依藥物類別
    • 非類固醇抗發炎藥
    • 抗憂鬱藥
    • 抗憂鬱藥
    • 抗憂鬱藥
    • 阿片類藥物
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 外用
    • 其他
  • 市場分析、洞察與預測：依分銷管道
    • 醫院藥房
    • 零售和線上藥房
  • 市場分析、洞察與預測：依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美慢性腰痛治療市場分析：洞察與預測

（2021-2034）
  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲慢性腰痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區慢性腰痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 東南亞亞洲
    • 亞太其他地區

第九章：拉丁美洲慢性腰痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲慢性下背痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2026）
  • 公司公司簡介
  • Pfizer Inc.
  • Lilly
  • GSK plc
  • Johnson &Johnson Services, Inc.
  • Merck &Co, Inc.
  • Sanofi
  • Novartis AG
  • Dr. Reddy's Laboratories
  • Bayer AG
  • Endo International plc.
Product Code: FBI100575

Growth Factors of chronic lower back pain (CLBP) treatment Market

The global chronic lower back pain (CLBP) treatment market is experiencing robust growth due to the rising prevalence of chronic pain conditions and increasing focus on long-term pain management solutions. According to the report, the market was valued at USD 2.84 billion in 2025 and is projected to grow to USD 3.10 billion in 2026, reaching USD 6.95 billion by 2034, exhibiting a CAGR of 10.63% during the forecast period. North America dominated the market with a 47.90% share in 2025, driven by high disease burden, strong healthcare infrastructure, and active pharmaceutical research.

Market Overview

Chronic lower back pain is one of the most prevalent musculoskeletal disorders globally and a leading cause of disability. The condition is commonly associated with osteoarthritis, degenerative disc disease, obesity, anxiety, and aging-related disorders. Management of CLBP includes pharmacological therapies such as NSAIDs, opioids, antidepressants, and analgesics, along with non-pharmacological approaches like rehabilitation and physical therapy. The growing economic burden caused by delayed diagnosis and lack of awareness has prompted governments to introduce guidelines and policies aimed at improving early management and treatment outcomes.

Market Drivers

The increasing prevalence of chronic lower back pain is a key factor driving market growth. Sedentary lifestyles, obesity, psychological stress, and aging populations have significantly increased the number of patients requiring long-term pain management. Government initiatives, such as the Australian Atlas of Healthcare Variation introduced in 2022, are improving awareness and encouraging early intervention, thereby boosting treatment demand. Additionally, pharmaceutical companies are accelerating research and development to introduce innovative drugs that provide effective and sustained pain relief.

Market Trends

A major trend shaping the market is the use of advanced drug delivery technologies to reduce dependency on traditional opioids. Long-term opioid use is associated with addiction and side effects, prompting researchers to focus on safer alternatives such as topical therapies and transdermal delivery systems. Several drugs are currently under clinical development, including Sorrento Therapeutics' SP-103 and Teikoku Pharma's flurbiprofen tape, reflecting strong innovation momentum in this market.

COVID-19 Impact

The COVID-19 pandemic temporarily slowed market growth in 2020 due to reduced non-essential medical consultations and limited access to pain management therapies. Pharmacological and non-pharmacological treatments declined during this period, particularly NSAID usage. However, post-pandemic recovery has been strong, with increased demand for OTC analgesics and renewed focus on R&D activities. Product launches and rising sales of pain relief medications supported positive revenue growth after 2021.

Segmentation Analysis

By drug class, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) dominated the market, accounting for 25.77% share in 2026, owing to their affordability, effectiveness, and over-the-counter availability. Opioids held the second-largest share, primarily prescribed for severe pain relief, while antidepressants and analgesics contributed notable revenue due to their effectiveness in chronic pain management.

By route of administration, the oral segment led the market with a 44.38% share in 2026, supported by high patient compliance, ease of use, and cost-effectiveness. Topical formulations such as gels and ointments also witnessed steady growth due to their localized and temporary pain relief benefits.

By distribution channel, retail and online pharmacies dominated with a 91.83% share in 2026, driven by improved accessibility, expanding online platforms, and increased availability of OTC pain medications.

Regional Insights

North America accounted for USD 1.36 billion in 2025, maintaining its leadership due to advanced drug development activities and high prevalence of chronic pain. Asia Pacific is expected to grow at the fastest rate, supported by cost-effective generic drugs and rising elderly populations. Europe is projected to register the second-highest growth, driven by sedentary lifestyles and increasing musculoskeletal disorders.

Competitive Landscape

The market is fragmented, with key players such as Johnson & Johnson Services, Inc., Bayer AG, GSK plc, Pfizer Inc., Sanofi, and Novartis AG focusing on expanding product portfolios, strategic collaborations, and regulatory approvals to strengthen their market presence.

Conclusion

The global chronic lower back pain treatment market is set for strong expansion, growing from USD 2.84 billion in 2025 to USD 6.95 billion by 2034, driven by rising disease prevalence, increasing awareness, and continuous innovation in pain management therapies. While alternative non-pharmacological treatments pose challenges to drug adoption, sustained R&D efforts, advanced drug delivery technologies, and expanding access to affordable medications are expected to support steady market growth throughout the forecast period.

Segmentation By Drug Class

  • Non-steroidal Anti-Inflammatory Drugs
  • Antidepressants
  • Analgesic
  • Opioids
  • Others

By Route of Administration

  • Oral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Chronic Lower Back Pain, By Key Countries, 2026
  • 4.2. Pipeline Analysis, Key Players
  • 4.3. Key Industry Developments, Key Players
  • 4.4. Impact of COVID-19 on the Market

5. Global Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 5.1.2. Antidepressants
    • 5.1.3. Analgesic
    • 5.1.4. Opioids
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Topical
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail & Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2029

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 6.1.2. Antidepressants
    • 6.1.3. Analgesic
    • 6.1.4. Opioids
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Topical
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 7.1.2. Antidepressants
    • 7.1.3. Analgesic
    • 7.1.4. Opioids
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Topical
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail & Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 8.1.2. Antidepressants
    • 8.1.3. Analgesic
    • 8.1.4. Opioids
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Topical
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail & Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Australia
    • 8.4.5. South East Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 9.1.2. Antidepressants
    • 9.1.3. Analgesic
    • 9.1.4. Opioids
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Topical
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail & Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Non-steroidal Anti-Inflammatory Drugs
    • 10.1.2. Antidepressants
    • 10.1.3. Analgesic
    • 10.1.4. Opioids
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Topical
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail & Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview,
      • 11.2.1.2. Products,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Lilly
      • 11.2.2.1. Overview,
      • 11.2.2.2. Products,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GSK plc
      • 11.2.3.1. Overview,
      • 11.2.3.2. Products,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Johnson & Johnson Services, Inc.
      • 11.2.4.1. Overview,
      • 11.2.4.2. Products,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co, Inc.
      • 11.2.5.1. Overview,
      • 11.2.5.2. Products,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sanofi
      • 11.2.6.1. Overview,
      • 11.2.6.2. Products,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview,
      • 11.2.7.2. Products,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Dr. Reddy's Laboratories
      • 11.2.8.1. Overview,
      • 11.2.8.2. Products,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview,
      • 11.2.9.2. Products,
      • 11.2.9.3. SWOT Analysis,
      • 11.2.9.4. Recent Developments,
      • 11.2.9.5. Strategies,
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Endo International plc.
      • 11.2.10.1. Overview,
      • 11.2.10.2. Products,
      • 11.2.10.3. SWOT Analysis,
      • 11.2.10.4. Recent Developments,
      • 11.2.10.5. Strategies,
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 2: Global Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 3: Global Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 4: Global Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 5: North America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 6: North America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 7: North America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 8: North America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 10: Europe Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 11: Europe Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 12: Europe Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 13: Asia Pacific Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 14: Asia Pacific Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 15: Asia Pacific Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 17: Latin America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 18: Latin America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 19: Latin America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Latin America Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 22: Middle East & Africa Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Chronic Lower Back Pain Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Chronic Lower Back Pain Treatment Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Chronic Lower Back Pain Treatment Market Value Share (%), By Drug Class, 2026 & 2034
  • Figure 3: Global Chronic Lower Back Pain Treatment Market Value Share (%), By Route of Administration, 2026 & 2034
  • Figure 4: Global Chronic Lower Back Pain Treatment Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 5: Global Chronic Lower Back Pain Treatment Market Value (USD billion), By Region, 2026 & 2034
  • Figure 6: North America Chronic Lower Back Pain Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 7: North America Chronic Lower Back Pain Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 8: North America Chronic Lower Back Pain Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 9: North America Chronic Lower Back Pain Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 10: North America Chronic Lower Back Pain Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 11: North America Chronic Lower Back Pain Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 12: North America Chronic Lower Back Pain Treatment Market Value (USD billion), by Country, 2026 & 2034
  • Figure 13: North America Chronic Lower Back Pain Treatment Market Value Share (%), by Country, 2026
  • Figure 14: Europe Chronic Lower Back Pain Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 15: Europe Chronic Lower Back Pain Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 16: Europe Chronic Lower Back Pain Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 17: Europe Chronic Lower Back Pain Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 18: Europe Chronic Lower Back Pain Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 19: Europe Chronic Lower Back Pain Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 20: Europe Chronic Lower Back Pain Treatment Market Value (USD billion), by Country/ Sub-Region, 2026 & 2034
  • Figure 21: Europe Chronic Lower Back Pain Treatment Market Value Share (%), by Country/ Sub-Region, 2026
  • Figure 22: Asia Pacific Chronic Lower Back Pain Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 23: Asia Pacific Chronic Lower Back Pain Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 24: Asia Pacific Chronic Lower Back Pain Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 25: Asia Pacific Chronic Lower Back Pain Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 26: Asia Pacific Chronic Lower Back Pain Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 27: Asia Pacific Chronic Lower Back Pain Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 28: Asia Pacific Chronic Lower Back Pain Treatment Market Value (USD billion), by Country/ Sub-Region, 2026 & 2034
  • Figure 29: Asia Pacific Chronic Lower Back Pain Treatment Market Value Share (%), by Country/ Sub-Region, 2026
  • Figure 30: Latin America Chronic Lower Back Pain Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 31: Latin America Chronic Lower Back Pain Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 32: Latin America Chronic Lower Back Pain Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 33: Latin America Chronic Lower Back Pain Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 34: Latin America Chronic Lower Back Pain Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 35: Latin America Chronic Lower Back Pain Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 36: Latin America Chronic Lower Back Pain Treatment Market Value (USD billion), by Country/ Sub-Region, 2026 & 2034
  • Figure 37: Latin America Chronic Lower Back Pain Treatment Market Value Share (%), by Country/ Sub-Region, 2026
  • Figure 38: Middle East & Africa Chronic Lower Back Pain Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 39: Middle East & Africa Chronic Lower Back Pain Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 40: Middle East & Africa Chronic Lower Back Pain Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 41: Middle East & Africa Chronic Lower Back Pain Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 42: Middle East & Africa Chronic Lower Back Pain Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 43: Middle East & Africa Chronic Lower Back Pain Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 44: Middle East & Africa Chronic Lower Back Pain Treatment Market Value (USD billion), by Country/ Sub-Region, 2026 & 2034
  • Figure 45: Middle East & Africa Chronic Lower Back Pain Treatment Market Value Share (%), by Country/ Sub-Region, 2026
  • Figure 46: Global Chronic Lower Back Pain Treatment Market Share Analysis, By Company, 2026